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TITLE: “EVALUATION OF BACTERIAL AND FUNGAL AGENTS IN THE
AETIOLOGY OF CHRONIC SUPPURATIVE OTITIS MEDIA WITH
SPECIAL REFERENCE TO  ANTIMICROBIAL RESISTANCE PATTERN
OF PSEUDOMONAS SPECIES”
ABSTRACT
Introduction:
Chronic  suppurative otitis  media is defined as chronic inflammation of
middle ear and mastoid cavity that presents with recurrent ear discharge of more than
three months duration through a perforated tympanic membrane.
CSOM is a major health problem in developing countries causing serious local
damage and threatening complications. It is an important cause of preventable hearing
loss in developing countries.
               Evaluation of the microbiological agents and their antimicrobial sensitivity
pattern in that region  is helpful in the initiation  of specific therapy and  thus
minimizing its complications and emergence of resistant  strains.
Aim:
          To determine the microbiological profile and their antimicrobial sensitivity
pattern in patients with chronic suppurative otitis media, with special reference to
antimicrobial resistance patterns of Pseudomonas species.
Materials and Methods:
This study was conducted at the Institute of Microbiology ,Madras Medical
college, Chennai . A total of 100 patients with clinical diagnosis of CSOM from the
Upgraded Institute of Otorhinolaryngology were enrolled in the study and the samples
were obtained from each patient using sterile cotton swabs and   processed by standard
microbiological techniques. Detection of  Extended spectrum betalactamases
(ESBL),AmpC betalactamases and Metallo betalactamases in Pseudomonas isolates
were done  by phenotypic methods.
 Results:
Analysis of bacterial flora of the present study showed predominance of Gram
negative bacilli. The highest incidence  was that of Pseudomonas aeruginosa (39.6%)
followed by Staphylococcus aureus(31.68%). In the present study for all the isolates
Amikacin was found to be the most effective drug followed by ciprofloxacin and
gentamicin. Antimicrobial susceptibility of Pseudomonas aeruginosa revealed 100%
sensitive to imipenem,97% sensitive to piperazillin-tazobactum,78% to amikacin
,75% to ciprofloxacin , 68% to gentamicin and 46% to ceftazidime.
ESBL producers in Pseudomonas aeruginosa was found to be 17.07%,AmpC
betalactamase was found in 9.75% .
Conclusion:
 The emergence of  P. aeruginosa possessing combinations of ?-lactamases
like ESBL and AmpC betalactamases is a major public health concern necessitating
efficient detection and intervention to control drug resistance. Hence continuous and
periodic evaluation of  microbiological pattern and antibiotic sensitivity is essential to
reduce the potential risk of complications and emergence of resistant strains.
1INTRODUCTION
Chronic  suppurative otitis  media is defined as chronic inflammation of
middle ear and mastoid cavity that presents with recurrent ear discharge of
more than three months duration through a perforated tympanic membrane. (1)
CSOM is a major health problem in developing countries causing
serious local damage and threatening complications. It is an important cause of
preventable hearing loss in developing countries.
             Incidence of this disease is higher among people with low socio-
economic status because of malnutrition, overcrowding, poor hygiene,
inadequate health care, and recurrent upper respiratory tract infection.
It is a massive health problem and India is one of the countries with
highest CSOM prevalence (> 4%) where urgent attention is needed.(1) It causes
conductive and sensorineural hearing loss and has got adverse effect on
childhood development. (2)  It is a common cause of hearing impairment and
can occasionally lead to fatal intracranial complications. Hence early and
accurate diagnosis of CSOM is life saving.
Both Gram positive and Gram negative bacteria are responsible for
infection of the middle ear in addition to fungal etiological agents. Due to
advent of newer antibiotics, the microbial organisms and their resistance
pattern is changing constantly.
2               Evaluation of the microbiological agents and their antibiotic
sensitivity pattern in that region  is helpful in the initiation  of specific therapy
and  thus minimizing its complications and emergence of resistant  strains.
Due to the long period of morbidity of CSOM and the repeated
occurrences of otorrhea during that period, patients  are often prescribed
empiric antibiotics in outpatient clinics without microbiologic evaluation.
CSOM has received considerable attention not only because of its high
incidence and chronicity but also because of issues such as bacterial resistance
and ototoxicity with both topical and systemic antibiotics .
The most common microorganisms found in CSOM are Pseudomonas
aeruginosa, Staphylococcus aureus, Klebseilla pneumoniae, Proteus mirabilis,
Escherichia coli, Aspergillus spp, Candida spp and these vary in different
geographical distributions.(4) Fungal infections of the middle ear  are common
as fungi thrive well in moist pus.
Therefore, this study was undertaken to know the pattern of microbes
and their antimicrobial susceptibility pattern to provide a guideline for
empirical antibiotic therapy.
Pseudomonas aeruginosa, one of the most common organism isolated in
CSOM  is an important cause of nosocomial infection which has developed
resistance to many potent antibiotics .Hence the antimicrobial resistance pattern
of Pseudomonas species was also analysed in this study.
3Though the treatment of CSOM is controversial, and subject to change
particularly in developing countries, the antibiogram of these organisms have
been reported to vary with time and geographical area, probably due to use and
abuse of antibiotics. Hence the need for periodic update of  antibiogram for
effective chemotherapy and management of CSOM cannot be overemphasized.
4AIMS AND OBJECTIVES
AIMS
To determine the Microbiological profile and their antimicrobial
sensitivity pattern in patients with chronic suppurative otitis media, with
special reference to antimicrobial resistance patterns of Pseudomonas species .
OBJECTIVES
1. To isolate aerobic bacterial and fungal agents causing CSOM.
2. To identify the antimicrobial susceptibility pattern of the bacterial
isolates.
3. To determine  the resistance pattern of Pseudomonas species
4. To detect Extended spectrum betalactamases (ESBL),AmpC
betalactamases and Metallo betalactamases in Pseudomonas
isolates by phenotypic methods.
4. To correlate the association of risk factors with Chronic
suppurative otitis media.
5REVIEW OF LITERATURE
DEFINITION
Chronic suppurative otitis media (CSOM) is defined as a chronic
inflammation of the middle ear and mastoid cavity, which presents with
recurrent ear discharges or otorrhoea through a tympanic perforation.(1) Though
the WHO definition requires only two weeks of otorrhea(1), otolaryngologists
tend to adapt a duration of more than 3 months of active disease.(2)
CSOM  is classified into two types depending on the site of perforation.
Tubotympanic
Also called the safe or benign type, involving the anteroinferior part of
the middle ear cleft and is associated with central perforation. There is no risk
of serious complications.
Atticoantral
Also called the unsafe or dangerous type, involving the posterosuperior
part of the middle ear cleft and is associated with attic or marginal perforation.
The disease is associated with bone eroding process such as cholesteotoma or
granulations and the risk of complications are high in this type of disease.(3)
Anatomy of the Ear
Anatomically ear is divided into three parts
61. External  ear
Consists of  Pinna ,external auditory canal and the tympanic membrane.
The external auditory canal  has two parts ,outer one third cartilaginous
and inner two thirds bony.
Tympanic membrane is a greyish white membrane set obliquely which
separates the external ear from the middle ear. It consists of  two parts
Pars Tensa : forms most  part of tympanic membrane. It  is peripherally
thickened to form a fibrocartilagenous ring called annulus which fits in the
tympanic sulcus.
Pars  Flaccida :is the  superior part of tympanic membrane.
Parts of the  Ear–External, Middle and Internal Ear
72. Middle Ear
Consists of the middle ear cavity with the Eustachian tube,the aditus ,the
mastoid antrum and the air cells of the mastoid.
The middle ear cavity lies between the tympanic membrane laterally and
the promontory formed by the basal turn of the cochlea medially  and is divide
into i) mesotympanum(lying opposite the pars tensa), ii) epitympanum  or the
attic( lying above the pars tensa) ,iii)hypotympanum(lying above the level of
pars tensa).
3. Inner Ear
The inner ear or the labyrinth is an important organ for hearing and
balance. It comprises the cochlea, vestibule, and semicircular canals.
Vestibulocochlear nerves connect the inner ear with the brain.
Epidemiology
The prevalence of CSOM varies between racial and socioeconomic
groups. Some of the risk factors identified include history of recurrent acute
suppurative otitis media, adverse socioecomic status, overcrowded and limited
access to medical care.(4) Worldwide, there are between 65-330 million people
affected, of whom 60% presents with significant hearing loss.  This burden
falls disproportionately on children in developing countries.(11)
WHO has categorized prevalence rates of 1-2% as  low and 3-6% as
high prevalence group.
8Country prevalence rates by WHO regional classification has
categorized India as high prevalence group. (prevalence rate > 4%).(1)
Incidence of  CSOM in India is 46/1000(rural population)and 16/1000(urban
areas) (23). It is one of the most common causes of hearing impairment in India
because of its prevalence in poor socio economic class.(24)
CSOM produces mild to moderate conductive hearing loss in more than
50% of the cases.(1). This is due to the disruption of ear drum and ossicles
which causes conductive hearing loss or from hair cell damage with the
bacterial infection which has gone into the middle ear (sensory hearing loss) or
both (mixed hearing loss).(1)
TUBOTYMPANIC TYPE OF CSOM
Tubotympanic Type of CSOM
In this, the disease is confined to the mucosa of Eustachian tube and
anteroinferior part of middle ear. It is called safe or benign type of disease as
there is no danger to the life of patient.
9Predisposing factors
It is a sequelae of acute suppurative otitis media (ASOM) which has not
been treated adequately.
Occasionally, a traumatic perforation may get infected leading to
CSOM.
Ascending infections via Eustachian tube, infections from tonsils,
adenoids and infected sinuses may be responsible for persistent or recurring
otorrhoea.(3)
Abnormal Eustachian tube function is a predisposing factor seen in
children with cleft palate and Down’s syndrome.(4). Other factors include
allergy, malnutrion, hypogammaglobulinemia, and unhygienic personal habits
like bathing and swimming in dirty water.
Viral infection would affect the mucosa of the middle ear making it less
resistant to the organisms that are normally present in the middle ear ,allowing
bacterial overgrowth.(2)
CSOM is often associated with poor mastoid pneumatisation. Though
mastoid pneumatisation begins in the latter half of embryonic development, the
greater part of this takes place in the first five years of life. Poor mastoid
pneumatisation are due to
 1. Infection in infancy or early childhood prevents normal cellular
development.
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 2. Infection within a pueumatized cleft provokes sclerosis,with
obliteration of the cells.
 3. Failure of air-cell development predisposes to infection of the
middle ear(4)
Pathogenesis
The pathological changes seen in tubotympanic  type of CSOM are
1. Perforation of the pars tensa
2. Chronic inflammation of middle ear mucosa:
Hyperemia and glandular hypertrophy causing profuse discharge occurs
when the disease is active. It may be normal when disease is quiescent or
inactive.
3. Polyp: A polyp is  a smooth mass of oedematous and inflamed
mucosa  which has protruded through a perforation and presents
in the external canal.It is usually pale in  contrast to pink, fleshy
polp seen in atticoantral disease.
4. Tympanosclerosis: It is hyalinisation and subsequent calcification
of the subepithelial connective tissue seen in the remnants of
tympanic membrane ,ossicles ,tendons ,oval and round  windows
causing conductive hearing loss.
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5. Ossicular chain: Fibrosis and adhesions occur as a result of
healing process impairing the mobility of ossicular chain. (3)
CLINICAL FEATURES
Tubotympanic type
Ear discharge : may be continous or intermittent and varies in character
from serous or mucoid or frankly purulent.
Hearing loss : predominantly conductive type of hearing loss. Factors
influencing the degree of conductive deafness include size of the perforation,
impairment of the ossicular chain and presence of middle ear pathology such as
oedema and granulation tissue.
Investigation
Examination under microscope: provides information regarding the
presence of granulations, edges of perforation, tympanosclerosis and adhesions.
Audiometry:  gives an assessment of degree of hearing loss and its type
which is usually conductive hearing loss.
Culture and sensitivity of ear discharge: to identify the pathogens and to
select the appropriate antibiotic topical or systemic
Mastoid X rays usually sclerotic may be pneumatised with no evidence
of bone destruction.
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Complications of Tubotympanic type
Includes
Otitis externa, erosion of ossicular chain, sensory neural hearing loss,
vertigo, tympanosclerosis and adhesions in the middle ear.
ATTICOANTRAL TYPE OF CSOM
Atticoantral Type of CSOM
It is also called unsafe or dangerous type of CSOM, as the disease
spreads to bony walls of epitympanum, aditus, antrum and mastoid cells
causing serious complications.
Predisposing factors
Cholesteotoma (skin in wrong place) keratinising squamous epithelium
replaces the  ciliated columnar epithelium of the middle ear cleft.
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Middle ear mucosa  undergoes metaplasia due to repeated infections and
transforms to squamous epithelium.
It may also be caused by localised osteitis in which granulations are seen
in the attic region.
Pathogenesis
The pathological changes in atticoantral disease include
? Retraction pocket in the attic due to negative intratympanic
pressure
? Granulation tissue with keratin masses or flakes providing ideal
medium for the growth of bacteria.
? Ossicular necrosis and Cholesterol granuloma(3)
Clinical features
Ear discharge: usually scanty and foul smelling due to bone destruction.
blood stained discharge indicates presence of granulation and underlying
osteitis.
Signs
Perforation: small attic perforation may be missed due to presence of
small amount of crusted discharge.
Retraction pocket: an invagination of tympanic membrane is seen in the
attic or posterosuperior part of pars tensa.
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Cholesteotoma: pearly white flakes of cholesteotoma can be seen in the
retraction pockets.
Investigations
Examination under microscope gives information about the extent of the
defect, the presence of squamous epithelium, keratin debris and involvement of
the ossicular chain or osteitis.
X ray Mastoids  useful in the demonstration of anatomical variation and
to detect bony erosion.
Culture and sensitivity of the ear discharge to select proper antibiotics.
Computed Tomography is generally the imaging modality of choice in
the assessment of cholesteotoma.
Complications of Attico antral type
They are classified into intracranial and extracranial complications.
Intacranial:  Mastoiditis, petrositis, facial paralysis and labrynthitis.
Extracranial: Extradural and subdural abscess, meningitis, brain abscess,
lateral sinus thrombosis and otitic hydrocephalus.
Although incidence of complications is declining, these are still seen in
india due to poor socio economic conditions ,lack of education and awareness
of health care. WHO studies shows that India and Sub-Saharan Africa (SSA)
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account for most deaths and years of life lost and DALYs(disability-adjusted
life-years) from otitis media.(1)
Management of CSOM
The principal aims of management are the eradication of infection and
the closure of the tympanic perforation.
Medical
Treatment with appropriate antibiotics based on antibiotic susceptibility
test is effective in bacteriological cure.
Surgical
Correction of hearing loss and closure of tympanic membrane
perforation requires appropriate surgical procedures.
Microbiological Profile of CSOM
A wide range of organisms, both aerobic and anaerobic may be isolated
from cases of CSOM. Although the development if CSOM may follow an
initial acute infection, the type of micro-organisms found in chronic discharge
differ from those found in acute suppurative otitis media.(2)  The predominance
of Gram negative organisms indicates the source of infection is not the
nasopharynx, which does not contain these organisms.(2).These organisms are
likely to gain access to the middle ear from the external auditory canal through
the tympanic membrane defect.(4)
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VARIOUS ISOLATES IN CHRONIC SUPPURATIVE OTITIS MEDIA
Aerobic isolates
Gram positive Bacteria
Staphylococcus aureus
Coagulase Negative Staphylococcus aureus
Streptococcus pneumoniae
Gram negative bacteria
Pseudomonas aeruginosa,
Klebsiella pneumonia,
Proteus species,
Escherichia coli,
Acinetobacter species
Morganella morgagnii
Anaerobic isolates
Clostridium species,
Peptococcus species,
Peptostreptococcus species,
Bacteroides species.
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Fungal isolates
Aspergillus niger,
Aspergillus fumigates,
Candida species
Though these bacteria are infrequently found in  the external auditory
canal ,they may cause infection of the middle ear due to  trauma,inflammation
or humidity  and  are most likely to gain access to the middle ear from the
external auditory canal  through the perforation(4).Pseudomonas aeruginosa has
been particularly responsible for deep seated infections and progressive
destruction of the  middle ear and mastoid through its toxins and enzymes.
In a study by Rajat Prakash(6) the most common organism isolated was
Staphylococcus aureus followed by Pseudomonas aeruginosa whereas in a
study by V.K.Poorey, and Arati lyer, the commonest isolate was Pseudomonas
aeruginosa followed by Klebsiella species(7). Many of the previous studies
showed Pseudomonas to be the most predominant isolate.(25,26,27,28,29).
Microbiological characteristics of  Pseudomonas species
Pseudomonas are ubiquitous microorganisms ,found in the environments
such as water, soil, plants, humans, animals, sewage and hospilats. In humans
they are opportunistic pathogens and has great propensity to grow in a variety
of environments with minimal nutritional components.(16)
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 It is resistant to the common antiseptics and disinfectants,such as
quaternary ammonium compounds, chloroxylenol and hexachlorophene and
may even grow profusely in bottles of  antiseptic lotions .
Historical Perspective
Until the first half of twentieth century ,the description  were inadequate
in terms of phenotypic characterisation. Work performed at the university of
California,Berkeley proposed the system  of classification  of pseudomonas
species based on phenotypic characteristics.(Stainer et al.1966).Later this was
followed by DNA-DNA hybridisation studies  that constituted a group that was
not phylogenitically uniform.
A clear demonstration of the phylogenetic heterogenicity was eventually
achieved by ribosomal RNA(rRNA)-DNA hybridisation as an analytical
criterion(Palleroni et al.1973).(17)
Classification
Palleroni separated the pseudomonas into five ribosomal RNA
homology groups based on rRNA-DNA homology studies whereas Gilardi
separated pseudomonas into seven major groups based on phenotypic
charecteristics.(18)
Phenotypic and Genotypic classification of Pseudomonas is  as given
below.
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RNA Group I
Fluorescent Group :   P.aeruginosa, P. Fluorescens, P. putida.
           Stutzeri group         :  P.stutzeri,P.mendocina,CDC Group Vb-3.
           Alkaligenes Group :  P.alcaligenes,P.pseudoalcaligenes ,
                                              Pseudomonas species group 1 .
RNA Group II
Pseudomallei Group    : Burkholderia mallei,Burkholderia pseudomallei
                                             Burkholderia cepacia complex,
                                             Burkholderia gladioli,Pandoraea species,
                                             Ralstonia species,Cupriavidus species.
RNA Group III
Weak Oxidiser Group  : Comamonas acidovorans,C.terrigena,C.testosteroni,
                                             Acidovorax delafieldii,A.facilis,A.temperans,
                                             Lautropia mirabilis, CDC WO-1.
RNA Group IV
Diminuta Group : Brevundimonas diminuta,B.vesicularis.
RNA Group V  : Stenotrophomonas maltophila
Yellow-Pigmented Group:   P.luteola,P.orizohabitans,
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                                              Sphingomonas.paucimobilis.
H2S-Positive Group: Shewanella putrifaciens,Shewanella algae.
Halophilic Group: Alishewanella fetalis,Halomonas venusta,
                                             CDC halophilic nonfermenter group 1
Morphology and Cultural Characteristics
? Pseudomonas aeruginosa are straight gram negative rod
measuring 0.5 to 0.8 µm by 1.5 to 3.0 µm ,that are strict aerobes
and motile by means of polar flagellum.They utilise glucose and
other carbohydrates oxidatively and are cytochrome oxidase
positive.
? P.aeruginosa grow well on ordinary media ,and produce a
characteristic fruity grape like odour.
? On MacConkey agar they grow as non lactose fermenting
colonies with green pigmentation or  metallic sheen.
? On Blood agar the colonies  appear as large colonies with
metallic sheen, mucoid, rough,or pigmented  and  often beta
haemolytic.
? The colonies of Pseudomonas aeruginosa are usually of two
types on most solid media.
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? One is large and smooth with flat,edges and elevated centres and
the other is smooth, rough and convex.Clinical isolates are
generally of  large type ,while the small type is commonly
obtained from natural sources.Variation of the large type  to
small is observed frequently but the reverse is rare.
? A third type of mucoid colony can be obtained from respiratory
and urinary tract secretions.The mucoid morphotype is due to the
production of polysaccharide ,alginate that surrounds the cell.
? Additional colony types can be observed and Jessen(1965) states
that at least five types may be distinguished but the type of
colony cannot be correlated  with other properties of the strain.(17)
? Circular,smooth colonies.
Irregular,contoured colonies
Dry,flat colonies
Mucoid colonies
Rugose colonies
Biochemically they are nonfermenter, oxidase positive which can grow
optimally at 37? C and can be distinguished from the others in the group by its
ability to grow at 42? C.They exhibit the characteristic pigment production of
pyocyanin and pyoverdin.
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Key Characteristics  of Fluorescent group
TEST P.aeruginosa P.fluorescens P.putida
Pyoverdin + + +
Pyocyanin + _ _
Acetamide V _ _
Growth at 42 C + _ _
No3 reduction V(74) V(19) _
Gelatin hydrolysis V(46) + _
+ , 90% or more strains positive
- , 90%or more srains negative
V, 11-89%of strains positive.
PIGMENTATION
Fluorescent (pyoverdin)Pigment
The Fluorescent group is characterised by production of water soluble
pyoverdin  pigment that fluoresces white to blue-green under ultraviolet light.
Pyocyanin pigment
Though all the three members of fluorescent group produce pyoverdin,
P.aeruginosa is the only species that produces the distinctive blue pyocyanin
pigment.
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Other water soluble pigments include pyorubin and pyomelanin which
imparts red and brown colour respectively.
Pigment production can be enhanced by using Tech and Flo media
which contains special peptones and increased concentration of magnesium and
sulphate ions.
Other methods to enhance pigment production is by growing the
organisms in gelatin, potato or milk containing media.
Virulence factor
Pseudomonas aeruginosa is the most common opportunistic pathogen of
all pseudomonas species .It  produces several substances that enhance the
colonization and infection of host tissue.
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Virulence Factors of Pseudomonas aeruginosa
Virulence Factor Biological activity
Alginate Capsular polysaccharide helps to adhere to the epithelial
surface of lungs  and forms biofilms.
Pili Surface appendages that cause adherence to GM-1
ganglioside receptors of epithelial cell surfaces.
Neuraminidase Removes sialic acid residues from GM -1 ganglioside
receptors,facilitation binding of pili.
Lipopolysacchari
de
Produces endotoxin which causes sepsis syndrome.
Exotoxin A Tissue destruction,inhibition of protein synthesis.
Enterotoxin Interrupts normal gastrointestinal activity,leading to
diarrhoea.
Exoenzyme S Inhibits protein synthesis.
Phosholipase C Destroys cytoplasmic membrane,destroys pulmonary
surfactant,inactivates opsonins.
Elastase Cleaves immunoglobulins and complement,distrups
neutrophil activity.
Leukocidin Inhibits neutrophil and lymphocyte function.
Pyocyanins Suppress other bacteria and distrups respiratory ciliary
activity,cause oxidative damage to tissues particularly
lung.
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Of all the extracellular enzymes produced by P.aeruginosa, exotoxin A
is the most toxic causing inhibition of peptide chain elongation and protein
synthesis.(17)
Resistance to antibiotics
P.aeruginosa is notorious for its resistance to antibiotics with more than
50 resistant genes.
The general resistance is due to combination of factors such as low
permeability of the cell wall, genetic capacity to express a wide repertoire of
resistance mechanisms, resistance through chromosomal mutations and
acquiring resistant gene from other organisms via plasmids, transposons and
bacteriophages.
The three major mechanisms by which the organisms resist the action of
antimicrobial agents include
 1. Restricted uptake and efflux
2. Drug inactivation and
3.  Mutational changes in target enzymes.(13)
Mechanisms of Resistance
Intrinsic Resistance
Intrinsic Resistance is mediated through multiple efflux pumps,resulting
in expulsion of betalactams, chloramphenicol, fluroquinolones, macrolides ,
sulphonamides ,tetracycline and trimethoprim.
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Extrinsic Resistance
Various antibiotics that overcome the intrinsic resistance include,
extended spectrum penicillins (piperacillin, ticarcillin),certain third and fourth
generation cephalosporins,(ceftazidime and cefipime),carbapenem (imipemem
and meropenem),monobactams(aztreonam),fluoroquinolones(ciprofloxacin and
levofloxacin),aminoglycosides (gentamicin, tobramycin, and amikacin) and
colistin.
But  mutational resistance can develop for these antibiotics.
Penetration of antibiotics through cell wall
The outer membrane of P. aeruginosa presents a significant barrier to
the penetration of antibiotics, restricting the rate of penetration of small
hydrophilic molecules and excluding larger molecules.
Hydrophilic antibiotics such as ß-lactams and quinolones can only cross
the outer membrane by passing through the aqueous channels provided by
porin proteins. These porin proteins are barrel shaped associated as trimers.
OprD is a specialized porin which has a specific role in the uptake of positively
charged amino acids.
Impermeability Mutations is important in carbapenem resistance  due to
the loss of OprD porin, a protein that forms a narrow transmembrane  channel
permeable to carnapenems but not betalactams.
Loss of oprD is frequently associated with resistance to imipenem,
which requires this porin to cross the outer membrane. Interestingly,
meropenem is not affected by loss of oprD, indicating that the carbapenems
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have crossed the outer membrane by different channels.(13). Resistance to
aminoglycosides and colistin has due to overexpression of an outer membrane
protein, oprH, which protects the LPS from binding the antibiotics has been
observed in laboratory strains of P.aeruginosa but less frequently in clinical
isolates.(30)
Efflux Pumps
Efflux pumps play an important role in multi drug resistant  comprising
of  three protein components,  an energy-dependent pump located in the
cytoplasmic membrane,  an outer membrane porin and  a linker protein which
couples the two membrane components together.(31)
The different antibiotic efflux systems  that have been described in P.
aeruginosa are mexAB-oprM, mexXY-oprM, mexCD-oprJ and mexEF-
oprN.(32)
mexAB-oprM is responsible for extrusion of ß-lactams, quinolones and
a range of disinfectants. mexXY-oprM extrudes aminoglycosides mexEF-oprN
extrudes carbapenems and quinolones.
The genes are present in all strains but they are not expressed at high
levels. However, increased expression  result from mutation of the regulatory
genes such as mexR, which controls  expression of the mexAB-oprM genes.(33).
Mutation or upregulation of mexR repressor gene results in efflux pump
overproduction and  increase in the minimum inhibitory concentration(MIC) of
multiple antibiotics but not imipenem.
28
DRUG INACTIVATION
Inactivation of aminoglycosides occurs through production of enzymes
which transfer acetyl, phosphate or adenylyl groups to amino and hydroxyl
substituents on the antibiotics. The modifying enzymes are plasmid mediated,
consequently spontaneous mutations in cells during antibiotic treatment does
not lead to overexpression of the enzymes, as seen with the chromosomal ß-
lactamases.
CHANGES IN TARGET ENZYMES
In P. aeruginosa  changes in target enzymes is most commonly
encountered with the quinolones through mutation in the gyrA gene encoding
the A subunit of the target enzyme, DNA gyrase.(34)
METHODS TO DETECT ANTIBIOTIC RESISTANCE MECHANISMS
Phenotypic methods
Extended Spectrum Betalactamase
Represent betalactamases that hydrolyze extended-spectrum
cephalosporins (cefotaxime, ceftriaxone, ceftazidime), monobactams
(aztreonam) and are not affected by betalactamase and carbapenemase
inhibitors. (35)
Confirmatory methods
? Double disk diffusion synergy test(39)
? Three dimensional test
? Inhibitor potentiated disc diffusion test(39)
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? ESBL E-strip method
? ESBL agar medium
Amp C betalactamase detection
Isolates showing reduced susceptibility to cefoxitin were considered as
screen positive  and selected for detection of Amp C betalactamases.
Confirmatory methods
? Amp C disc test
? Modified three dimensional test(40)
? Amp C betalactamase E test(40)
Carbapenemase detection
A strain that produces carbapenemases presents at least 21 mm diameter
to meropenem, imipenem or ertapenem is considered to be positive for
Carbapenemase production. (36)
? Confirmatory methods
? Modified Hodge test
? Imipenem- EDTA combined disc test
? Imipenem EDTA double disc synergy test
? MBL E-test
? CARBA NP test
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MATERIALS AND METHODS
This cross sectional  study was conducted in the Institute of
Microbiology, in association with Upgraded institute of Otorhinolaryngology,
Madras Medical College ,Rajiv Gandhi Government General Hospital,
Chennai.
Study period
The study period is for a period of 1 year from October 2014 to
September 2015.
Study Population
100 patients with clinical diagnosis of CSOM attending ENT
department of RGGGH who satisfied the inclusion criteria were enrolled for
the study.
Ethical consideration
Approval was obtained from the Institutional ethics committee before
the commencement of the study. Informed consent was obtained from all the
patients who participated in the study.
Statistical analysis
Statistical analysis were carried out using Statistical Package for Social
Sciences(SPSS).The proportional data of this cross sectional study were tested
using One sample Z-test.
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Study population
A total of 100 patients with clinical diagnosis of CSOM from the
Upgraded Institute of Otorhinolaryngology ,RGGGH ,Chennai  were include in
the study.
Inclusion criteria
? Patients with clinical diagnosis of CSOM
? Patients older than 13 years.
? Patients who were not on antibiotic (both systemic and topical)
treatment for minimum of 24 hours prior to sample collection.
Exclusion criteria
? Patients less than 13 years.
? Patients with acute otitis media.
? Patients not willing to participate in the study.
Sample collection
The ear discharge was collected using sterile swabs  under aseptic
precautions with the aid of an aural speculum, prior to the instillation of any
topical medication. Using sterile swabs .A minimum of three samples were
taken. First swab used for direct Gram stain and KOH mount,Second swab for
bacterial culture and the third swab for fungal culture based on the KOH
mount.
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Specimen processing
? Direct Gram stain :
Shows possible pathogens present in sample.
? KOH mount:
Detection of fungal elements.
Interpretation of bacterial culture
The swab on reaching the laboratory was inoculated on the following
culture media
? Nutrient agar plate
? Mac Conkey agar plate
? 5% Sheep Blood agar plate
After overnight incubation at 37?C aerobically, the plates were
examined for growth and culture characteristics were identified.
The isolates were identified by Grams stain morphology, motility,
culture characteristics and biochemical reactions by the standard techniques.
The isolated colonies depending on the Gram reaction were subjected to
following biochemical tests for identification.
If Gram negative bacilli was seen ,the colonies were subjected to the
following tests and biochemical reactions using standard micobiological
techniques.
1. Catalase  test
2. Oxidase test
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3. Nitrate reduction test
4. Hugh-Leifson’s Oxidation Fermentation test
5. Indole test
6. Methyl red test
7. Voges Proskauer test
8. Simmon’s Citrate utilization test
9. Christensen’s Urease test
10. Mannitol motility
11. Triple sugar iron agar
12. 1% Sugar fermentation tests Glucose,Sucrose,Maltose,Mannitol.
13. Lysine decarboxylase,Ornithine decarboxylase and Arginine
dihydrolase test.
Identification of Pseudomonas species was based on the following
culture characteristics and biochemical reactions.
On Nutrient agar- iridescent colonies with metallic sheen are seen.
On MacConkey agar - forms non-lactose fermenting colonies .
On Blood agar - many strains were hemolytic on blood agar. Some of
them were non  hemolytic.
Isolates that are GramNegative bacilli,catalase positive,oxidase positive
and motile by hanging drop were  identified as Pseudomonas species.
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Isolates were identified as  Pseudomonas  aeruginosa by  the following
characteristics
1. Gram Negative rod
2. Oxidase Positive
3. Fruity grape –like odour
4.  Growth at 42?C :P.aeruginosa is distinct from the rest of the
clinically relevant fluorescent pseudomonas in its ability to grow
at 42?C.
5. Nitrate reduction and gas from nitrate
6. Arginine dihyhrolase test :Positive
 7. Gelatin Hydrolysis :Positive
Acinetobacter speciation was done by the following additional tests
1. Presence of growth at 44?C
2. Presence of ß hemolysis
3. 10% OF lactose utilization test
4. Malonate utilization.
Isolates that are Gram Positive cocci were subjected to the following
tests and biochemical reactions using standard techniques.
1.  Catalase test
2.  Coagulase test  -Slide and Tube coagulase
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3.  Modified Oxidase test
4.  Urease Test
5. Mannitol fermentation test
6. Phenolphthalein phosphatase test
7. Gelatin Liquifaction test
8. Bacitracin susceptibility test using 0.04U disk.
If the Gram positive cocci in clusters that  were catalase positive and
coagulase negative  it was identified as Coagulase negative Staphylococci and
the following additional tests were  done for speciation of  CONS.
1. Carbohydrate fermentation tests using Lactose, Mannitol,
Mannose, Xylose and Trehalose
2. Nitrate reduction test
3. Ornitine decarboxylase test
4. Differential disc diffusion test with Novobiocin (5µg) and
Polymyxin 300 units.
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ANTIBIOTIC SUSEPTIBILITY TESTING
Isolates were subjected for antibiotic susceptibility testing by employing
Kirby-Bauer standard disc diffusion method on Muller- Hinton agar according
to CLSI guidelines (M100-S24)
Antimicrobial susceptibility testing by Kirby-Bauer Disc diffusion method
1. With a sterile bacteriological wire loop 3-5 well isolated identical
colonies were picked up  and inoculated in 5ml of  peptone water,
incubated at 37?C for 3-5 hrs to attain 0.5 McFarland’s turbidity.
2.  A sterile cotton swab was dipped into it and pressed firmly
against the wall of the test tube to remove excess broth from the
swab.
 3. Dried surface of Mueller Hinton agar plate was swabbed in three
directions 60? each time to ensure an even and complete
distribution of  the  inoculums over the entire plate.
4.  Inoculated plate was   allowed to dry for 3 to 5 minutes with the
lid in place before adding the antibiotic discs.
5. The antimicrobial discs were placed on the surface of the agar
using forceps. Not more than 6 discs were placed in the plate.
6. After overnight incubation at 37?C, the diameter of zone of
inhibition was  measured in mm.
Interpretation of Zone of inhibition diameters were done according to
CLSI guidelines.
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ATCC control strains:
? Staphylococcus aureus–ATCC 25923
? Escherichia coli-ATCC 25922
? Pseudomonas aeruginosa-ATCC 27853
? Klebsiella pneumoniae (ESBL)-ATCC 700603
The panel of  drugs used for antimicrobial susceptibility test of Gram
Positive organisms were as follows
Antibiotic Disc content
Zone of  Inhibition in mm
Sensitive Intermediate Resistant
Penicillin 10 units ? 29 - ?28
Erythromicin 30µg ?23 14-22 ?13
Ciprofloxacin 5µg ?21 16-20 ?15
Amikacin 30?g ?17 15-16 ?14
Cotrimoxazole 1.25/23.75?g ?16 11-15 ?10
Chloramphenicol 30?g ?18 13-17 ?12
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The panel of  drugs used for antimicrobial susceptibility test of Gram
Negative organisms were as follows
Antibiotic
Disc
content
Gram negative
bacilli
Diameter of Zone of inhibition
 in mm.
Sensitive Intermediate Resistant
Amikacin 30?g Enterobacteriaceae
&Non-fermenters
? 17 15-16 ? 14
Ciprofloxacin 5 ?g Enterobacteriaceae
&Non-fermenters
?21 18-20 ?17
Gentamicin 10?g Enterobacteriaceae
&Non-fermenters
?15 13-14 ?12
Cotrimoxazole 1.25/
23.75?g
Enterobacteriaceae
&Non-fermenters
?16 11-15 ?10
Piperacillin-
Tazobactam
100?g
/10?g
Enterobacteriaceae
&Non-fermenters
?21 18-20 ?17
Cefotaxime 30?g Enterobacteriaceae ?26 23-25 ?22
Acinetobacter ?23 15-22 ?14
Ceftazidime 30?g Enterobacteriaceae ?21 18-20 ?17
P.aeruginosa&
Acinetobacter sp.
?18 15-17 ?14
Imipenem 10?g Enterobacteriaceae ?23 20-22 ?19
P.aeruginosa ?19 16-18 ?15
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All the  isolates of  Pseudomonas aeruginosa were screened for ESBL,
AmpC and MBL production by the following methods. The screen test positive
isolates were subjected to respective confirmatory tests using appropriate
antibiotic discs.
Extended spectrum ß-lactamase(ESBL)  detection method.
Pseudomonas aeruginosa showing reduced zone of inhibition around
ceftazidime(30µg) with reference to CLSI 2014 AST criteria  were considered
to be ESBL producers.
Using sterile loop, four or five colonies of similar morphology were
picked up, inoculated to 5ml peptone water and incubated at 37?C for 4-6hrs
until turbidity matches with McFarland 0.5 turbidity standard (1.5x108cfu/ml).
Lawn culture was done on Mueller-Hinton agar plates and Ceftazidime and
Ceftazidime-clavulanic acid discs  are placed 50mm apart from centre to
centre.
Interpretation
Zone of inhibition was measured around the discs with the help of
measuring scale. An increase in 5 mm in zone of inhibition in a disc containing
clavulanic acid compared to the drug alone is considered as an ESBL producer.
AmpC ß lactamases detection methods
Screening for AmpC ß-lactamase
Pseudomonas isolates were screened for AmpC ß-lactamase by using
cefoxitin (30µg).Isolates  showing reduced susceptibility to cefoxitin (30µg)
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with zone diameter less than 18mm were considered as  positive and selected
for the detection of AmpC ß-lactamases by  Amp C disc test.(37)
Amp C disc test
? A lawn culture of ATCC E.coli 25922 was prepared on MHA
plate.
? Sterile discs of 6mm size was moistened with sterile saline and
inoculated with several colonies of test organism.
? The inoculated disc was then placed beside a cefoxitin disc
(almost touching on the  inoculated plate.The plates were
incubated overnight at 35?C.
? Flattening or indentation of the cefoxitin inhibition zone in the
vicinity of the test disc were considered as AmpC  positive
isolate.
? A negative test had an undistorted zone.
Metallo-ß-lactamase (MBL) detection method
Screening method for MBL
Pseudomonas isolates were screened for Metallo-ß-lactamase production
by using  imipenem (10µg).
Isolates with zone of inhibition less than 15mm were considered as
MBL producers.(38).
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DETECTION OF METHICILLIN RESISTANCE  IN
STAPHYLOCOCCUS AUREUS
Isolates of Staphylococcus  aureus were screened for MRSA by standard
disc diffusion using cefoxitin(30µg).Isolates with zone of inhibition less than
21mm were considered as Methicillin resistant Satphylococcus aureus.
FUNGAL CULTURE
KOH Mount
Direct microscopic examination of the ear discharge was done in 10%
KOH. for the presence of epithelial cells ,pus cells, budding yeast cells ,fungal
hyphae and spores.
One large drop of 10% KOH was placed on a clean grease free slide
mounted with a small quantity of specimen and is mixed well.A sterile cover
slip is placed over the drop and left at room temperature for 10 mts for the
digestion of the debris.The mount is examined under low and high power for
the presence of epithelial cells ,pus cells,budding yeast cells ,fungal hyphae and
spores.
INTERPRETATION OF FUNGAL CULTURE
Based on the KOH mount, the ear discharge was also inoculated onto 2
slopes of  Sabourad’s dextrose agar of pH 5.6 with antibiotics like gentamicin
to inhibit bacterial growth and incubated at 25?C  and 37?C for  4-6 weeks.The
slopes were examined daily during first week and twice a week for the next
three weeks.failure of growth even after six weeks was considered as negative
for fungal growth and were discarded.
42
The  significance of fungal culture ,in case of commensal or
opportunistic fungi being  isolated can be established by the following features.
? Isolation of  same fungal isolate from all the culture tubes.
? Direct microscopic confirmation of the fungal elements.
? Repeated isolation of the isolate from multiple specimens.
Tubes showing positive cultures were examined for macroscopic and
microscopic  appearance of the colonies. Any visible growth on either of the
slants were examined for Rate of growth, texure, surface pigmentation,
pigmentation on the reverse, presence of diffusible pigment.
Microscopic examination was done by Lactophenol cotton blue(LPCB)
mount
A drop of LPCB was placed on a grease free slide and a small amount of
fungal colony midway between the colony edge and centre was placed on the
LPCB drop. The growth was teased so as to have a thin spread out  and a
coverslip is gently dropped to the edge of the mounting fluid to avoid air
bubbles. The  mount is examined under the  microscope.
Identification is based on the following characteristics
? Nature of hyphae (such as septate or aseptate,hyaline or
phaeoid,narrow or wide)
? Conidiogenesis (origin,arrangement)
? Conidia (septate,Pigmented or hyaline,shape and conidial wall)
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RESULTS
This cross sectional study was conducted in the Institute of
Microbiology, Madras Medical College in association with the Upgraded
Institute of Otorhinolaryngology, at the Rajiv Gandhi Government General
Hospital, Chennai .
A total of 100 patients with  CSOM who satisfied the inclusion criteria
were included in the study.Out of  100 patients  93 were culture positive while
7 samples showed no growth.
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TABLE 1: ANALYSIS OF AGE DISTRIBUTION IN CSOM
Age Distribution
Vs Culture
Results
Number
of Cases
Positive
Cases %
NO
Growth %
11-20 Years 8 5 5.38 3 42.86
21-30 Years 26 24 25.81 2 28.57
31-40 years 24 24 25.81 0 0.00
41-50 Years 16 15 16.13 1 14.29
51-60 Years 16 15 16.13 1 14.29
61-70 Years 9 9 9.68 0 0.00
71-80 Years 1 1 1.08 0 0.00
Total 100 93 100 7 100
Table 1 shows the Age wise distribution of the morphotypes in CSOM.
Maximum number of patients were in the second  decade of life.
FIG. 1:  ANALYSIS OF AGE DISTRIBUTION IN CSOM
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TABLE 2:  ANALYSIS OF GENDER DISTRIBUTION
Gender Distribution Frequency Percentage
Male 57 57
Female 43 43
Total 100 100
P value One Sample Z-Test 0.321
The gender distribution were studied and was found that Males
outnumbered females in the ratio of    1.3 : 1.
FIG.2:  ANALYSIS OF GENDER DISTRIBUTION
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TABLE : 3  DISTRIBUTION OF RISK FACTORS ASSOCIATED
WITH  CSOM
Associated Features Number
URTI 42
Allergy 18
Tonsillitis 15
DNS 43
FIG. 3:  DISTRIBUTION OF RISK FACTORS ASSOCIATED
WITH CSOM
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TABLE 4 : DISTRIBUTION OF UNILATERAL AND
 BILATERAL CSOM
Number %
Unilateral CSOM 95 95%
Bilateral CSOM 5 5%
Among the 100 patients included in the study, 95 patients has unilateral
ear discharge and 5 had bilateral ear discharge .
FIG. 4: DISTRIBUTION OF UNILATERAL AND BILATERAL CSOM
UNILATERAL  (95)
95%
BILATERAL (5)
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UNILATERAL AND BILATERAL CSOM
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TABLE 5: DISTRIBUTION ACCORDING  TO THE TYPE OF CSOM
Type of CSOM Number %
Tubotympanic CSOM 88 88.00
Atticoantral CSOM 12 12.00
Total 100 100
P value One Sample Z-Test 0.0018
FIG. 5: DISTRIBUTION ACCORDING TO THE TYPE OF CSOM
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TABLE 6 :  ANALYSIS OF  CULTURE RESULTS
Culture results Number Percentage
Positive 93 93%
Negative 7 7%
FIG. 6: ANALYSIS OF CULTURE RESULTS
93%
7%
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TABLE 7 : MONOMICROBIAL AND  POLYMICROBIAL
DISTRIBUTION IN CSOM
Age Vs
microbial
Isolates
Monomicrobial % Polymicrobial %
11-20 Years 5 5.61% 0 0.00
21-30 Years 23 25.84% 2 28.57%
31-40 years 20 22.47% 4 57.14
41-50 Years 15 16.85% 0 0.00
51-60 Years 3 3.37% 0 0.00
61-70 Years 22 24.71% 1 14.28%
71-80 Years 1 1.12% 0 0.00
Total 89 100% 7 100%
Monomicrobial growth was seen in  89  patients,  whereas polymicrobial
growth was observed in  7 patients .
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TABLE 8: MICROBIAL PROFILE
Organism No.of Isolates %
Pseudomonas aeruginosa 41 39.81
Klebsiella pneumonia 7 6.80
Escherichia coli 5 4.85
Proteus mirabilis 4 3.88
Acinetobacter baumannii 3 2.91
Staphylococcus aureus 32 31.07
Staphylococcus epidermidis 5 4.85
Aspergillus niger 4 3.88
Aspergillus fumigatus 2 1.94
Total 103 100
FIG. 7: MICROBIAL PROFILE
41
7
54
3
32
5 4
2
Microbial Profile
Pseudomonas aeruginosa
Klebsiella pneumonia
Escherichia coli
Proteus mirabilis
Acinetobacter baumannii
52
TABLE 9: DISTRIBUTION OF GRAM NEGATIVE
 BACTERIA IN CSOM
Gram Negative Bacteria No.of Isolates %
Pseudomonas aeruginosa 41 68.33
Klebsiella pneumoniae 7 11.67
Escherichia coli 5 8.33
Proteus mirabilis 4 6.67
Acinetobacter baumannii 3 5.00
Total 60 100
FIG.8. DISTRIBUTION OF GRAM NEGATIVE ISOLATES IN CSOM
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TABLE 10: ANALYSIS OF GRAM POSTIVE ISOLATES IN CSOM
Gram Positive Cocci No.of Isolates %
Staphylococcus aureus 32 86.49
Staphylococcus epidermidis 5 13.51
Total 37 100
FIG.9. ANALYSIS OF GRAM POSITIVE ISOLATES IN CSOM
TABLE :11 LIST OF FUNGI ISOLATED IN CSOM
Fungal No.of Isolates %
Aspergillus niger 4 66.67
Aspergillus fumigatus 2 33.33
Fungal culture was positive in 6 patients, out of which 4 were
A.fumigatus and 2 were A.niger.
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TABLE 12:ISOLATES  IN POLYMICROBIAL PROFILE
Orgainsms Number ofpatients
S.aureus +  E.coli 2
P.aeruginosa +  K.pneumoniae 1
 K.pneumonia+S.epidermidis 1
P.aeruginosa +S.aureus 1
S.aureus + A.baumannii 1
P.aeruginosa +A.niger 1
Total 7
FIG.10. ISOLATES ON POLYMICROBIAL PROFILE
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TABLE 13: ANTIMICROBIAL  SUSCEBTIBILITY OF THE
BACTERIAL ISOLATES
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Pseudomonas
aeruginosa
41 32 28 31 40 19 NT NT NT NT 41 NT
Klebsiella
pneumoniae
7 6 4 4 7 NT  3 1 NT NT NT NT
Escherichia coli 5 4 4 1 5 NT  2 1 NT NT NT NT
Proteus mirabilis 4 4 4 1 4 NT 1 NT NT NT NT NT
Acinetobacter
baumannii
3 3 3 3 3 1 2 NT NT NT 1 NT
Staphylococcus
aureus
32 29 NT 25 NT NT 28 NT 10 20 NT 32
Staphylococcus
epidermidis
5 5 0 4 NT NT 2 NT 2 3  NT  5
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TABLE 14.ANTOBIOTIC RESISTANCE  PATTERN OF BACTERIAL
ISOALATES
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Pseudomonas
aeruginosa 41 9 13 10 1 22 NT NT NT NT 0 NT
Klebsiella
pneumoniae 7 1 3 3 NT NT 4 6 NT NT NT NT
Escherichia
coli 5 1 1 4 NT NT 2 4 NT NT NT NT
Proteus
mirabilis 4 0 0 3 0  NT  3 4 NT NT NT NT
Acinetobacter
baumannii 3 0 0 0 0 2 1 NT NT NT NT NT
Staphylococcu
s aureus 32 2 NT 7 NT NT 3 NT 21 10 NT 0
Staphylococcu
s epidermidis 5 0 NT 1 NT NT 3 NT  3 2  NT  0
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TABLE 15 : ANTIBIOTIC  PROFILE  OF Pseudomonas aeruginosa
Pseudomonas
aeruginosa
N=41
Sensitive % Resistant %
P value One
Sample
Z-Test
Amikacin 32 78.05 9 21.95 0.0001
Gentamicin 28 68.29 13 31.71 0.0062
Ciprofloxacin 31 75.61 10 24.39 0.0091
Piperacillin &
Tazobactum
40 97.56 1 2.44 0.0001
Ceftazidime 19 46.34 22 53.66 0.5713
Imipenem 41 100.00 0 0.00 0.0001
FIG.11. ANTIBIOTIC PROFILE OF PSEUDOMONAS AERUGINOSA
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TABLE 16: ANTIBIOTIC PROFILE OF
STAPHYLOCOCCUS AUREUS
Staphylococcus
aureus
N=32
Sensitive % Resistant %
P value
One Sample
Z-Test
Amikacin 29 90.63 2 6.25 0.0001
Ciprofloxacin 25 78.13 7 21.88 0.0001
Cotrimoxazole 28 87.50 3 9.38 0.0001
Penicillin 10 31.25 21 65.63 0.0062
Erythromycin 20 62.50 10 31.25 0.0051
Chloramphenicol 32 100.00 0 0.00 0.0001
FIG.12. ANTIBIOTIC PROFILE OF STAPHYLOCOCCUS AUREUS
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TABLE 17: ANTIMICROBIAL SUSCEBTIBILITY PATTERN OF
KLEBSIELLA PNEUMONIAE
Klebsiella
pneumonia
N=7
Sensitive % Resistant %
P value
One Sample
Z-Test
Amikacin 6 85.71 1 14.29 0.0001
Gentamicin 4 57.14 3 42.86 0.3210
Ciprofloxacin 4 57.14 3 42.86 0.3210
Piperacillin &
Tazobactum 7 100.00 0 0.00 0.0001
Cotrimoxazole 3 42.86 4 57.14 0.3210
Cefotaxime 1 14.29 6 85.71 0.0001
FIG.13. ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF K.
PNEUMONIAE
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TABLE 18: ANTIMICROBIAL SUSCEPTIBILITY
PATTERN OF E.COLI
Escherichia coli
N=5
Sensitive % Resistant %
Amikacin 4 80.00 1 20.00
Gentamicin 4 80.00 1 20.00
Ciprofloxacin 1 20.00 4 80.00
Piperacillin &
Tazobactum
5 100.00 0 0.00
Cotrimoxazole 2 40.00 2 40.00
Cefotaxime 1 20.00 4 80.00
FIG 14: ANTIMICROBIAL SUSCEPTIBILITY
PATTERN OF E.COLI
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TABLE :19 ANTIMICROBIAL SUSCEPTIBILITY PATTERN
OF P.MIRABILIS
Proteus mirabilis
N=4
Sensitive % Resistant %
Amikacin 4 100.00 0 0.00
Gentamicin 4 100.00 0 0.00
Ciprofloxacin 1 25.00 3 75.00
Piperacillin &
Tazobactum 4 100.00 0 0.00
Cotrimoxazole 1 25.00 3 75.00
Cefotaxime 0 0.00 4 100.00
FIG. 15. ANTIMICROBIAL SUSCEPTIBILITY PATTERN
OF P.MIRABILIS
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TABLE 20: ANTIMICROBIAL SUSCEPTIBILITY PATTERN
OF A.BAUMANNII
Acinetobacter
baumanni
N=3
Sensitive % Resistant %
Amikacin 3 100.00 0 0.00
Gentamicin 3 100.00 0 0.00
Ciprofloxacin 3 100.00 0 0.00
Piperacillin &
Tazobactum
3 100.00 0 0.00
Ceftazidime 1 33.33 2 66.67
Cotrimoxazole 2 66.67 1 33.33
FIG.16. ANTIMICROBIAL SUSCEPTIBILITY PATTERN
OF  A.BAUMANNII
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TABLE 21: DETECTION OF ESBL IN PSEUDOMONAS
AERUGINOSA
ESBL Production No of isolates Percentage
Positive 7 17.07%
Negative 34 82.92%
TABLE 22: DETECTION OF AMPC BETALACTAMASE IN
PSEUDOMONAS AERUGINOSA
AmpC Beta Lactamase No.of Isolates Percentage
Positive 4 9.75%
Negative 37 90.24%
 TABLE 23: DETECTION OF MBL IN PSEUDOMONAS
AERUGINOSA
Screening Test for
MBL No of Isolates Percentage
 Positive 0 0.00%
 Negative 41 100%
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DISCUSSION
Chronic Suppurative Otitis Media(CSOM) is considered as a major
public health problem,in the developing world and India is one of the countries
with high prevalence where urgent attention is needed.(1)
It is a persistent disease with risk of irreversible complications and is an
important  cause of preventable hearing loss  in adults and  children.(41)
Since chronic suppurative otitis media is a disease which can cause
significant morbidity, early microbiological diagnosis ensures effective
treatment.(42) Hence knowledge of pathogens  and their antibiotic susceptibility
pattern would guide the treating physicians in selection of appropriate
antibiotics which would help us in reducing the complications and emergence
of resistant strains.(43)
This cross sectional study which was conducted in the Institute of
Microbiology in association with the Upgraded Institute of
Otorhinolaryngology, Madras Medical College,Chennai, included 100 patients
with clinical diagnosis of CSOM.
In the present study ,105 samples (pus from the middle ear) were
obtained  from 100 patients. Out of 100 patients, five had bilateral ear
discharge accounting for 105 samples. Among 100 patients 93  were culture
positive for aerobic bacteria and fungi.
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Out of the  five  patients who had bilateral ear discharge- one  patient
had the same organism infecting both the ears  and two had different organisms
affecting  each ear and two had growth in single ear .
Analysis of Age distribution showed peak  incidence of CSOM  in the
second decade of life. Prakash et al in their study has reported peak incidence
in the first decade of life.(8)
In the present  study   majority of patients had  tubotympanic type of
CSOM (88%)as compared to atticoantral type(12%). Sharma et al in their study
has documented 72% of the cases as the safe or tubotympanic type and 28%  as
atticoantral type.
Monomicrobial growth was seen in 89  patients, whereas 7 showed
polymicrobial  growth .No growth was observed in 7  samples .
Aslam et al, in their study showed that out of  142 samples studied ,
76% of them were pure and 23.9% were mixed cultures.(44) Poorey and lyer
from India  in their study isolated  pure growth from 82, mixed growth from 10
samples  out of 100 samples included..(45)
Analysis of bacterial profile  of the present study showed that   Gram
negative bacilli outnumbered  Gram positive cocci which is similar to studies
by Naheed  et al (51) and Kulchal et al(52). The predominant pathogen was
Pseudomonas aeruginosa (39.6%) , followed by  Staphylococcus aureus
(31.68%),   Klebsiella pnuemoniae(6.8%), Escherichia coli(4.8%), and Proteus
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mirabilis(3.8%)and Acinetobacter baumanii(2.9%). This is in  concordance
with many previous studies .(46,47,48,49,50)  Shyamala et al have found that
Pseudomonas aeruginosa and Staphylococcus species are the commonest
organism isolated from otitis media.(46) In contrast, Prakash et al in their study
has documented  Staphylococcus aureus to be the predominant isolate
comprising of  48.69%  of the total followed by Pseudomonas aeruginosa.
These studies depict that the microbial profile vary between different
regions,based on patient population and geographical distribution and hence
necessitates the need for frequent analysis and update of the microbial profile
in every region.
Pseudomonas aeruginosa, the predominant cause of CSOM in tropical
region  usually does not  inhabit the upper respiratory tract, its presence in the
middle ear cannot be ascribed to an invasion through Eustachian tube  and it is
considered to  gain access to the middle ear via defect in TM.
 Prakash et at(6) in their  study reported Coliforms including Klebsiella
pneumoniae and Escherichia coli  in  9.42% and 7.33% cases respectively,and
these findings were tandem to the study done by Mansoor et al.(57) who
reported K.peumoniae in 8% and E.coli in 4% whereas Poorey and lyer(45) in
their  study has reported a high incidence of  Klebsiella (25.4%).
A recent study by Shyamala and Reddy showed a different trend where
E. coli was reported in 12% and Klebsiella in 5% of cases.(53) Frequent isolation
of coliforms like Escherichia.coli and Klebsiella  indicates that individuals are
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at high risk of acquiring  infection when they are exposed to water
contaminated with faecal flora while bathing or in activities like swimming.
The Gram positive organisms isolated in the present study were
Staphylococcus aureus (31%) and S.epidermidis(4.8%)  which is similar to the
studies done by Ettehad  et al(68) and Singh et al(69) ,whereas  Prakash et al has
documented higher rate of isolation of Staphylococcus aureus(48.69%)  in their
study.
In the present study ,fungal culture was done in 25 patients  based on the
KOH mount and was positive in 6 patients.
Among the  six fungal isolates , four  were Aspergillus niger(66.67%)
and two were  Aspergillus fumigates(33.33%).  In a study from Haryana, India,
fungal etiology was found in 15% of cases, out of which 60% were Candida
species and 40% were Aspergillus species.(54).Sen Gupta et al reported  74.2%
of Aspergillus species and 19.3% of candida species among the fungal isolates.
(55) In contast U Mohan et al in their  study on 182 samples reported 25 fungal
isolates of which 60%were Candida species and 40% were Aspergillus
species.(56)
Antimicrobial  Susceptibility
In the present study, antibiotic susceptibility testing was done for all the
isolated organisms by Kirby-Bauer disc diffusion methodas per CLSI
guideliness. Antibiotic susceptibility pattern of  P.aeruginosa revealed 100%
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susceptibility to Imipenem, while 97%  of the isolates were sensitive to
Piperazillin-tazobactum,78% to Amikacin,75% to Ciprofloxacin, 68%to
Gentamicin and 46% to Ceftazidime.The sensitivity pattern of Pseudomonas
aeruginosa  was similar to the studies done by Gulati et al.,(58) and Mishra et
al(59 and Lee  et al (60) in which the authors have documented  100%
susceptibility to Imipenem followed by Piperacillin-Tazobactum,Amikacin and
Ciprofloxacin.
Mansoor T et al in their study   showed that amikacin was active against
96%  of the isolates of Pseudomonas, followed by ceftazidime (89%).(61)
Aminoglycosides  are bactericidal antibiotics that interfere with protein
synthesis and are frequently used because of its activity against Gram negative
bacteria. In the present study majority of  the Pseudomonas aeruginosa isolates
were found to be more sensitive to amikacin than gentamicin and this finding is
similar to  previous studies in Sharma et al ,Nepal(62),Saini et al ,India (63)and
Wario et al from Nigeria.(64)
Fluoroquinolones  inhibits the bacterial DNA gyrase or the
topoisomerase II thereby inhibiting DNA transcription and replication.They
have a broad range of activity and found to be active against Pseudomonas
aeruginosa.In the present study  75% of  P.aeruginosa was found to be sensitive
to ciprofloxacin which is similar to various studies  that has reported  90%
Sensitivity to ciprofloxacin.
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Ceftazidime is a most frequently prescribed third generation
cephalosporin that has an extended Gram negative spectrum. However
resistance to ceftazidime is increasing ,complicating the management of
patients with such isolates.
In the present study, 53% of  isolates of  P.aeruginosa were resistant to
Ceftazidime which is in concordance to the study conduced by Sabiranatah
 et al(65) in which 54% of the  Pseudomonas  isolates showed 54% resistance to
ceftazidime. Contrary to this ,  the study by  chavan et al (66) has reported 84%
sensitivity to ceftazidime.
Ceftazidime resistance is mainly mediated by production of ?-
lactamases such as ESBL, MBL and occasionally AmpC-?-lactamases (67)
Besides production of various ?-lactamases, other mechanisms such as the lack
of drug penetration due to mutation in porins, loss of certain outer membrane
proteins and efflux pumps may also contribute for resistance to ?-lactams.
In the present study the rates of ESBL,Amp C and MBL were
determined among the isolates of Pseudomonas resistant to ceftazidime.
In the present study out of 41  isolates of P.aeruginosa, (7) 17.07%   were
found to be positive for ESBL production.  These observations suggest that the
ESBLs which are generally widespread among members of Enterobacteriaceae
are also increasingly found in P. aeruginosa. This is in  concordance with the
studies of Aggarwal et al and Picao et al who documented  ESBL production of
about 21% .(70,71)
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ESBL producing organisms are frequently resistant to other classes of
ntibiotics, including aminoglycosides and fluoroquinolones  due to the
coexistence of genes encoding drug resistance to other antibiotics on the
plasmids which encode ESBL.
           With regard to AmpC ßlactamases in  the present study 9.75% of the
P.aeruginosa isolates were observed to produce AmpC producer but the study
done by Parveen et al, AmpC production was observed in 55.5% of the
ceftazidime resistant Pseudomonas spp (72).
All the isolates of P.aeruginosa were sensitive to Imipenem and there
were no MBL producers in the present study.
The second most commonly isolated organism in our study was
Staphylococcus aureus comprising of 32% of the isolates. All the isolate of
staphylococcus aureus were found to be methicillin sensitive(MSSA) where
90%of the isolates were  sensitive  to amikacin,87% to cotrimoxazole,78%  to
ciprofloxacin and  62% to Erythromycin.This correlates with  the reports of the
study done by Prakash et al where out of 181 isolates , 48% of isolates were
Staphylococcus aureus and all were found to be methicillin sensitive.
In our study Escherichia coli showed 80% sensitivity with Amikacin
20%  sensitivityto ciprofloxacin.The sensitivity of Proteus mirabilis was good
with amikacin and gentamicin. Klebsiella pneumoniae showed 85% sensitivity
with amikacin and 57% sensitivity with both ciprofloxacin, and  gentamicin.
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          CSOM is generally treated by oral medications with quinolone antibiotic
drops such as ciprofloxacin. The absence of oral formulations of Ceftazidime,
Cefipime and Imipenem has severely limited the use of these antibiotics in
patients with CSOM otorrhea, thus restricting the ability of these bacteria to
develop resistance to these antibiotics. This may explain,why resistance to
Imipenem in bacteria from CSOM otorrhea is lower than in other types of
bacterial infection. (73,74)
Multidrug resistant in Pseudomonas aeruginosa is classified as
resistance to more than three antimicrobial catagories.(75)
In the present study isolation rate of  multidrug resistant  Pseudomonas
aeruginosa was found to be 9.75%.Similar results were obtained in the study by
Lee et al.(76)
The present study has showed that CSOM infections are commonly
caused by Pseudomonas aeruginosa followed by Staphylococcus
aureus.However Pseudomonas infections are  becoming less sensitive against
commonly used antimicrobials like  ciprofloxacin, cephalosporins, and
gentamicin .Resistance to antimicrobial agents is an increasing public health
threat. It limits therapeutic options and leads to increased morbidity and
mortality. The important factor that is responsible for resistance is
inappropriate use of antibiotics.It is essential to follow antibiotic policies which
guides judicious and appropriate use antibiotics  to prevent emergence and
spread of resistant pathogens.
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Hence Continuous and periodic evaluation  of microbiological pattern
and antimicrobial sensitivity of the isolates  is necessary to decrease the risk of
complications and emergence of resistant microorganisms by early institution
of appropriate treatment.
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SUMMARY
? A total of 100 patients with clinical diagnosis of CSOM from the
Upgraded Institute of Otorhinolaryngology were included in the
study.
? There was a male predominance among the cases(57%)
? Analysis of age distribution  showed  maximum no of  patients
with CSOM  in the second decade of life.
? The risk factors associated include upper respiratory tract
infection,allergy,tonsillitis and deviated nasal septum. Many
patients had more than one  risk factor  associated with CSOM.
? Out of 100 patients ,88 patients had tubotympanic (safe) type of
CSOM,and 12 had atticoantral type of CSOM.
? Analysis of culture results showed culture positive in 93 patients
and no growth was observed in 7 patients.
? In the present study out of 100 patients ,95 patients had unilateral
CSOM and 5 had ear discharge from both the ears.
? Monomicrobial  growth was observed in 89 patients and
polymicrobial in 7 patients.All the 5 patients who had bilateral
CSOM had monomicrobial growth.One patient had the same
organism infecting both the ears and two had different organisms
affecting each ear and two had growth in single ear.
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? Analysis of bacterial flora showed predominance of
Pseudomonas aeruginosa (39.6%) followed by Staphylococcus
aureus(31.68%).
? The other Gram negative isolates isolated were Klebsiella
pneumonia(6.8%), E.coli,(4..8%). P.mirabilis(3.8%) and
Acinetobacter  baumannii(2.9%).
? The  Gram Positive organisms isolated include Staphylococcus
aureus(31.68%) and S.epidermidis(4.8%).
? In the present study fungal culture was done based on the KOH
mount and was positive in 6 patients .Among the six fungal
isolates,4 were A.niger and two were   A.fumigatus.
? In the present study for all the isolates Amikacin was found to be
the most effective drug followed by ciprofloxacin and
gentamicin.
? Antimicrobial susceptibility of Pseudomonas aeruginosa revealed
100% sensitive to imipenem,97% sensitive to piperazillin-
tazobactum,78% to amikacin ,75% to ciprofloxacin , 68% to
gentamicin and 46% to ceftazidime.
? ESBL producers in Pseudomonas aeruginosa was found to be
17.07%,AmpC betalactamase was found in 9.75%
? There were no MBL producers as all the isolates of P.aeruginosa
were sensitive to imipenem.
? Multidrug resistant Pseudomonas aeruginosa was found in 9.75%
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CONCLUSION
Chronic suppurative otitis media is a major health problem in
developing countries causing serious local damage and threatening
complications.
In the present study Pseudomonas aeruginosa was the major  pathogen
in the etiology of CSOM followed by staphylococcus aureus. These organisms
are found to  be less susceptible to the routinely used drugs like ciprofloxacin
and cephalosporins. This may be due to important factor that the cultures are
mostly requested when commonly used drugs have failed to eradicate the
infection. . Hence  appropriate antimicrobial drugs should be prescribed after
proper diagnosis of the causative organism and its antimicrobial susceptibility
pattern.
              The results of this study indicates that ESBL  and AmpC production is
a major mechanism of resistance  to cephalosporins  among the isolates of
P.aeruginosa.
             The emergence of P. aeruginosa possessing combinations of ?-
lactamases like ESBL and AmpC betalactamases is a major public health
concern necessitating efficient detection and intervention to control drug
resistance.
Hence continuous and periodic evaluation of  microbiological pattern
and antibiotic sensitivity is essential to reduce the potential risk of
complications and emergence of resistant strains.
DIRECT GRAM STAIN SHOWING GRAM NEGATIVE BACILLI
COLONIES OF PSEUDOMONAS AERUGINOSA
ON NUTRIENT AGAR PLATE
 COLONIES OF PSEUDOMONAS AERUGINOSA ON
BLOOD AGAR PLATE
AMPC DISC TEST FOR AMPC BETALACTAMASE DETECTION
PHENOTYPIC  CONFIRMATORY METHOD FOR ESBL
.
LPCB MOUNT OF ASPERGILLUS FUMIGATUS
LPCB MOUNT OF ASPERGILLUS NIGER
APPENDIX –I
ABBREVATIONS
CSOM - Chronic Suppurative Otitis Media
URTI - Upper Respiratory Tract Infection
DNS -       Deviated  Nasal Septum.
CLSI - Clinical & Laboratory Standards Institute
ATCC - American Type Culture Collections
GNB  - Gram Negative Bacilli
GPC - Gram Positive Bacilli
MH broth  - Mueller Hinton broth
MHA - Mueller Hinton Agar
MIC - Minimum Inhibitory Concentration
MRSA - Methicillin Resistant Staphylococcus aureus
MSSA - Methicillin Sensitive staphylococcus aureus
PCDDT - Phenotypic Confirmatory Disk Diffusion Test
DDST - Double Disc Synergy Test
ESBL - Extended Spectrum Beta Lactamase
MBL - Metallo BetaLactamase
MHT - Modified Hodge Test
LPCB - Lactophenol cotton blue
NT - Not tested
AK - Amikacin
GM - Gentamicin
CIP - Ciprofloxacin
PT - Piperacillin Tazobactum
CAZ - Ceftazidime
COT - Cotrimoxazole
CTX - Cefotaxime
PEN - Penicillin
ERY - Erythromycin
CX - Cefoxitin
IMP - Imipenem
CHLOR - Chloramphenicol
APPENDIX –II
A. STAINS AND REAGENTS
I.  Gram staining
Methyl violet (2%)  l0g Methyl violet in l00ml
absolute alcohol in 1litre of
distilled water (primary stain)
Grams Iodine  l0g Iodine in 20g KI
(fixative)
Acetone Decolourising agent
Carbol fuchsin 1% Secondary stain
II. 10% KOH
Potassium hydroxide l0g
Glycerol  l0ml
Distilled water 80ml
III. Lactophenol cotton blue stain:
Lactic acid 20 ml
Phenol 20ml
Cotton blue (dye) 0.5g
Glycerol 40ml
Distilled water 20ml
B. MEDIA USED:
1.  Nutrient agar
Peptic digest of animal tissue 5g
Sodium chloride 5g
Beef extract 1.5g
Yeast extract 1.5g
Agar 15gm
Final pH 7.4±0.2
Suspend 28 grams in 1000 ml distilled water. Heat to boiling to dissolve
the medium completely and sterilized by autoclaving at 15 lbs pressure
(120°C) for 15 minutes.
2.  Mac Conkey agar
Peptone 20g
Sodium taurocholate 5g
Distilled Water  1 ltr
Agar  20g
2% neutral red in 50% ethanol  3.5ml
10% lactose solution l00mI
Dissolve peptone and taurocholate in water by heating. Add agar and
dissolve it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well
and mix.Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15
minutes.
3.  Blood agar (5% sheep blood agar)
Peptone l0g
NaCl  5g
Distilled water 1 Ltr
Agar 10g
Dissolve ingredients in distilled water by boiling, and add 5% sheep
blood(sterile) at 55°C adjust pH to 7.4.
4. Sabouraud’s dextrose agar
Dextrose  40g
Peptone l0g
Agar 20g
Distilled water l000ml
pH = 5.5
Sterilise by autoclaving at 121ºC for 20 min
5.  Mueller Hinton Agar:
Ingredients Gms / Litre
Beef, infusion 300.000
Casein acid hydrolysate 17.500
Starch  1.500
Agar  17.000
Final pH (at 25°C) 7.3±0.1
Suspend 38 grams in 1000 ml distilled water. Heat to boiling to dissolve
the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for
15 minutes.
Cool to 50o C .Add aseptically 5ml of sterile sheep blood to 95 ml of the
agar. Mix well and dispense in aseptically into sterile petri dish.
B. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION:
1. Oxidase Reagent
Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution.
2. Catalase
3% hydrogen peroxide
3. Indole test
Kovac’s reagent
Amyl or isoamyl alcohol 150ml
Para dimethyl amino benzaldehyde 10g
Concentrated hydrochloric acid 50ml
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in
small quantities and store in the refrigerator. Shake gently before use.
4.  Christensen’s Urease test medium
Peptone  1g
Sodium chloride 5g
Dipotassium hydrogen phosphate 2g
Phenol red  6ml
Agar 20g
Distilled water 1 ltr
10% sterile solution of glucose  l0ml
Sterile 20% urea solution  l00ml
Sterilize the glucose and urea solutions by filtration. Prepare the basal
medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by
autoclaving in a flask at 121°C for 30min. Cool to about 50°C, add the glucose
& urea, and tube the
medium as slopes.
5. Simmon’s Citrate Medium
Koser’s medium 1 ltr
Agar 20g
Bromothymol blue 0.2% 40ml
Dispense, autoclave at 121°C for 15 min and allow to set as slopes
6. Triple Sugar Iron medium
Beef extract 3g
Yeast extract  3g
Peptone 20g
Glucose 1g
Lactose  l0g
Sucrose  l0g
Ferric citrate 0.3g
Sodium chloride 5g
Sodum thiosulphate 0.3g
Agar 12g
Phenol red 0.2% solution  l2ml
Distilled water 1 ltr
Heat to dissolve the solids, add the indicator solution, mix and tube.
Sterilize at 121°C for 15 min and cool to form slopes with deep butts.
7. Glucose phosphate broth
Peptone 5g
Dipotassium hydrogen phosphate  5g
Water 1 ltr
Glucose 10% solution  50ml
Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter
dispense in 5ml amounts and sterilize at 121°C for 15min. Sterilize the glucose
solution by filtration and add 0.25ml to each tube
Methyl Red Reagent
Methyl Red 10mg
Ethyl alcohol 30ml
Distilled water  20ml
Voges Proskauer Reagent
Reagent A:
Alpha naphthol 5g
Ethyl alcohol 100ml
Reagent B:
Potassium hydroxide 40g
Distilled water  100ml
8.  Peptone water fermentation test medium.
To the basal medium of peptone water, add sterilised sugars of 1%
indicator :bromothymol blue with Durham’s tube.
Basal medium peptone water
Sugar solutions:
Sugar 1ml
Dislilled water l00ml
pH = 7.6.
9. Mannitol motility medium
Agar 5g
Peptone 1g
Potassium nitrate 1g
Mannitol 2g
Phenol red indicator
Distilled water  l000ml
pH 7.2
11. Potassium nitrate broth
Potassium nitrate (KN03) 0.2gm
Peptone 5.0gm
Distilled water 100ml
The above ingredients were mixed and transferred into tubes in 5 ml
amount and autoclave.
12. 2% Sodium deoxycholate solution:
Ingredients :
Sodium deoxycholate 2 gms
Distilled water 100ml
Dissolve 2 gms of deoxycholate in 100 ml of distilled water .Mix
well.Store in a sterile containers.
8. Decarboxylase media:
8a. Moller decarboxylase broth base:
Ingredients gms/L
Peptone 5
Beef extract 5
Bromocresol purple 0.01
Cresol red 0.005
Glucose  0.5
Pyridoxal 0.005
Final pH 6
8b. Aminoacid:
Add 10 g of the levo form of the aminoacid for 1000ml.mix and
dispense in sterile tubes.
9. Hugh & Leifson’s Oxidation –Fermentation test:
Peptone  2g
Sodium chloride 5g
D-glucose 10g
Bromothymol blue 0.03g
Agar 3.0g
Dipotassium phosphate  0.30g
Distilled water 1L
pH =7.1
Basal medium is autoclaved.1% of sterile sugar solutions is added to the
basal medium.Dispense into sterile test tubes without slant.
ANNEXURE  –I
ANNEXURE  –II
PROFORMA
Name :                                                                            Age:
Sex:
Occupation:
Address:
Presenting complaints:
o Ear discharge   R/L/Both
o Difficulty in Hearing
o Ear Pain
o Ringing of ear
o Fever
o Vomiting
o headaches
History of presenting illness:
Past history:
Personal history:
Habits
Treatment History:
General physical examination:
Local examination:
Systemic examination:
Provisional diagnosis:
Investigations
X ray
Mastoids
Lateral View of the Face
Paranasal Sinus
CT scan findings:
Microbiological Investigations:
Direct examination:
      Gram stain-
      KOH mount-
Bacterial Culture:
? NA
? MAC
? BAP
Fungal culture:
? SDA
Isolate identified in sample:
Antibacterial susceptibility pattern:
ANNEXURE  –III
CONSENT FORM
STUDY TITLE
Evaluation of bacterial and fungal agents in the aetiology of chronic
suppurative otitis media with special reference to antimicrobial resistance
pattern of Pseudomonas species”
I…………………………………………, hereby give consent to
participate in the study conducted by Dr.SangeethaBaskaran, Post graduate at
Institute of Microbiology, Madras Medical College, Chennai and to use my
personal clinical data and the result of investigations for the purpose of analysis
and to study the nature of the disease.
I have read and understood this consent form and the information
provided to me.
I have had the consent document explained to me.
I have been explained about the nature of the study.
I have been explained about my rights and responsibilities by the
investigator.
I have been informed the investigator of all the treatments I am taking or
have taken in the past.
I have not participated in any research study within the past ________
month(s).
I am aware of the fact that I can opt out of the study at any time without
having to give my reason and this will not affect my future treatment in this
hospital.
I am also aware that the investigator may terminate my participation in
the study at any time, for any reason, without any consent.
I hereby give permission to the investigators to release the information
obtained from me as result of participation in this study to the sponsors,
regulatory authorities, Govt. agencies, and IEC. I understand that they are
publicly presented.
1. I have understand that my identity will be kept confidential if my
data are publicly presented.
2. I have had my questions answered to my satisfaction.
3. I have decided to be in the research study.
I am aware that if I have any question during this study, I should contact
the investigator. By signing this consent form I attest that the information given
in this document has been clearly explained to me and understood by me, I will
be given a copy of this consent document.
I also give consent to give my clinical sample(Pus) for further
investigations. I also learn that there is no additional risk in this study.
Name and signature / thumb impression of the participant
Name ___________________________________
Signature_________________________
Date________________
Name and Signature of the investigator
Name ___________________________________
Signature_________________________
Date________________
ANNEXURE  –IV
Master CHART
S
NO AGE SEX
EAR-
R/L/B
ASSOCIATED  FEATURES Type ofCSOM
Species
Identified ANTIBIOTIC SUSCEPTIBITITY TESTING
URTI ALLERGY TONSILLITIS DNS AK GM CIP PT CAZ COT CTX PEN ERY IMP CHLOR
RESIS
TANT
PATT
ERN
1 57 F R + _ _ _ AT P.aeruginosa S S S S S _ _ _ _ S _
2 26 F L _ _ _ + TT P.aeruginosa R R R S S _ _ _ _ S _
3 22 M B-R + _ + _ AT P.aeruginosa S S S S R _ _ _ _ S _
B-L S.aureus S _ S _ _ S _ R S _ S
4 55 M L _ _ _ _ TT P.aeruginosa S S S S R _ _ _ _ S _
5 18 F R _ + _ _ TT K.pneumonia S R S S _ R R _ _ _ _ ESBL
6 25 F L + _ _ + TT NG
7 56 M R _ _ _ + TT S.aureus S _ S _ _ _ _ R R _ S
8 38 F L + _ _ + TT P.aeruginosa R R R S R _ _ _ _ S _ AmpC
9 21 F R _ _ _ + TT S.aureus S _ R _ _ S _ S R _ S
10 45 F R + _ _ + AT P.aeruginosa S S R S S _ _ _ _ S _
11 57 F B-R _ _ _ + TT K.pneumonia S R R S _ R R _ _ _ _ ESBL
B-L NG
12 78 M R + _ _ _ TT S.aureus S _ S _ _ S _ R R _ S
13 45 F R _ _ + + TT S.aureus S _ S _ _ S _ R R _ S
14 21 M R + + _ _ TT E.coli S S S S _ R R _ _ _ ESBL
S.aureus S _ S _ _ S _ R S _ S
15 52 F R _ _ _ + TT NG
16 40 F R + _ _ _ TT P.aeruginosa S R S S R _ _ _ _ S _ AmpC
S
NO AGE SEX
EAR-
R/L/B
ASSOCIATED  FEATURES Type ofCSOM
Species
Identified ANTIBIOTIC SUSCEPTIBITITY TESTING
URTI ALLERGY TONSILLITIS DNS AK GM CIP PT CAZ COT CTX PEN ERY IMP CHLOR
RESIS
TANT
PATT
ERN
17 31 F R + + _ _ TT P.aeruginosa S R S S R _ _ _ _ S _ AmpC
K.pneumonia S S R S _ R R _ _ _ _ ESBL
18 60 M B-R + _ _ + TT S.aureus S _ S _ _ S _ R S _ S
B-L A.baumannii S S S S S S _ _ _ _ _
19 32 M R _ _ _ _ TT P.aeruginosa R R S S R _ _ _ _ S _
20 39 F L TT CONS S _ S _ _ S _ R R _ S
K.pneumonia S S S S _ S R _ _ _ _ ESBL
21 25 M L _ + _ _ AT P.aeruginosa S S S S R _ _ _ _ S _
A.niger
22 30 M B-R _ _ _ _ TT S.aureus S - R _ _ S _ R S _ S
L NG
23 49 M R + _ _ _ TT K.pneumonia R R R S _ R R _ _ _ _ ESBL
24 23 M L _ _ _ + TT S.aureus S _ S _ _ S _ R S _ S
25 29 F L _ _ _ _ TT S.aureus S _ S _ _ R _ R R _ S
26 52 F L _ _ _ _ TT A.niger
27 41 M L + _ _ _ TT NG
28 32 M R _ + _ + TT S.aureus S _ S _ _ S _ S S _ S
P.aeruginosa S S S S S _ _ _ _ S _
29 39 M R _ _ _ + TT S.aureus S _ S _ _ S _ S S _ S
30 48 F B-R + _ _ _ AT P.aeruginosa S S S S S _ _ _ _ S _
B-L P.aeruginosa S S S S S _ _ _ _ S _
31 21 M R + _ + _ TT P.aeruginosa S S S S S _ _ _ _ S _
S
NO AGE SEX
EAR-
R/L/B
ASSOCIATED  FEATURES Type ofCSOM
Species
Identified ANTIBIOTIC SUSCEPTIBITITY TESTING
URTI ALLERGY TONSILLITIS DNS AK GM CIP PT CAZ COT CTX PEN ERY IMP CHLOR
RESIS
TANT
PATT
ERN
32 26 M R _ _ _ + TT A.fumigatus
33 20 M L _ _ + _ TT S.aureus S _ R _ _ S _ R R _ S
34 65 M R _ _ _ + TT A.niger
35 39 M R _ _ + _ AT P.aeruginosa S S S S S S _
36 23 F R + _ _ _ AT P.aeruginosa R R S S R _ _ _ _ S _ ESBL
37 23 F R _ _ _ + TT S.aureus R R _ _ S _ S S _ S
38 13 M R + _ + _ TT NG
39 38 F R _ _ _ _ TT P.aeruginosa S S S S R _ _ _ _ S _
40 25 F L + _ _ _ TT P.aeruginosa S S S S S _ _ _ _ S _
41 27 F L _ _ _ + TT P.aeruginosa S S S S S _ _ _ _ S _
42 48 F R + _ _ + TT P.aeruginosa R R S S R _ _ _ _ S _ ESBL
43 20 M L _ + _ _ TT P.aeruginosa S S S S R _ _ _ _ S _
44 30 F L _ + _ + AT P.aeruginosa S S S S S _ _ _ _ S _
45 35 F R _ _ _ _ TT P.aeruginosa R R S S R _ _ _ _ S _ ESBL
46 14 M R _ + _ + TT E.coli S S R S _ _ R _ _ _ _ ESBL
47 34 F L _ _ _ _ TT P.aeruginosa R R S S S _ _ _ _ S _
48 58 M L _ _ _ + AT P.aeruginosa S S S S R _ _ _ _ S _
49 63 M L + _ _ _ TT P.aeruginosa S R S S R _ _ _ _ S _
50 35 F L _ + _ _ TT S.aureus S _ S _ _ S _ R S _ S
51 15 F L + _ + + TT NG
52 21 F L _ + + _ TT P.aeruginosa S S R S R _ _ _ _ S _
53 50 M L _ _ _ _ TT P.aeruginosa S S S S R _ _ _ _ S _
S
NO AGE SEX
EAR-
R/L/B
ASSOCIATED  FEATURES Type ofCSOM
Species
Identified ANTIBIOTIC SUSCEPTIBITITY TESTING
URTI ALLERGY TONSILLITIS DNS AK GM CIP PT CAZ COT CTX PEN ERY IMP CHLOR
RESIS
TANT
PATT
ERN
54 64 F R + _ _ _ AT P.aeruginosa S S S S S _ _ _ _ S _
55 23 M R + _ + + TT CONS S _ S _ _ S _ R S _ S
56 22 M R _ _ _ + TT P.aeruginosa R R R S S _ S _
57 60 M R + _ _ + TT S.aureus _ _ S _ _ S _ R R _ S
58 34 F L _ _ _ _ TT S.aureus S _ R _ _ S _ R _ _ S
E.coli S S R S _ S R _ _ _ _ ESBL
59 37 M L _ _ _ _ AT P.aeruginosa R R R S R _ _ _ _ S _
60 37 M R + _ _ _ TT E.coli S S R S _ S S _ _ _ _
61 35 M L _ _ _ + TT Proteusmirabilis S S S S _ R R _ _ _ _ ESBL
62 55 F L _ _ _ _ TT S.aureus S _ S _ _ S _ R S _ S
63 22 M R + + _ + TT S.aureus S _ S _ _ S _ S S _ S
64 68 M R + _ _ _ TT CONS S _ S _ _ R _ S S _ S
65 40 M R _ _ _ _ TT E.coli R R R S _ R S _ _ _ _
66 36 M L _ + _ _ TT S.aureus S _ R _ _ R _ R R _ S
67 35 M R + _ + + TT P.aeruginosa S S R S R _ _ _ _ S _ ESBL
68 67 M R + _ _ _ TT S.aureus S _ S _ _ S _ S S _ S
69 38 M L + + _ _ TT Proteusmirabilis S S R S _ R R _ _ _ _
70 47 F R _ _ _ _ TT P.aeruginosa S S S S S _ _ _ _ S
71 46 M R _ _ _ + TT S.aureus S _ S _ _ S _ S S _ S
72 56 F R + _ _ _ TT P.aeruginosa S S S S S _ _ _ _ S _
73 27 M R _ + + + TT S.aureus S _ S _ _ S _ R S _ S
S
NO AGE SEX
EAR-
R/L/B
ASSOCIATED  FEATURES Type ofCSOM
Species
Identified ANTIBIOTIC SUSCEPTIBITITY TESTING
URTI ALLERGY TONSILLITIS DNS AK GM CIP PT CAZ COT CTX PEN ERY IMP CHLOR
RESIS
TANT
PATT
ERN
74 49 M R + _ _ _ TT S.aureus S _ S _ _ S _ R S _ S
75 67 M R _ _ _ + TT S.aureus S _ S _ _ S _ R R _ S
76 60 M R + _ _ _ TT S.aureus R _ R _ _ R _ R R _ S
77 55 M L + _ + _ TT CONS S _ R _ _ R _ R R _ S
78 34 F L _ _ _ _ TT A.niger
79 55 F R _ _ _ + TT S.aureus S _ S _ _ S _ R S _ S
80 22 M L + + _ + TT S.aureus S _ S _ _ S _ S S _ S
81 56 M L _ _ _ _ TT P.aeruginosa S S S S S _ _ _ _ S _
82 25 M L _ _ _ + TT S.aureus S _ S _ _ S _ S S _ S
83 19 M L _ + _ _ TT NG
84 45 F L _ _ _ _ TT A.baumannii S S S S R R _ _ _ _ _
85 50 M L _ _ _ _ TT Proteusmirabilis S S R S _ R R _ _ _ _ ESBL
86 45 F R + _ _ _ TT K.pneumonia S S S S S R _ _ _ _ ESBL
87 30 F L + _ _ _ TT K.pneumonia S S S S S S _ _ _ _
88 50 F R _ _ _ _ TT P.mirabilis S S R S S R _ _ _ _ ESBL
89 25 M R + + _ + TT NG
90 63 M L + _ _ _ TT A.baumannii S S S S R S _ _ _ S _
CONS S _ S _ _ R _ S S _ S
91 46 M R _ _ + + TT P.aeruginosa S S S S S _ _ _ _ S _
92 28 F R + + + + TT P.aeruginosa S S S S S _ _ _ _ S _
93 37 F L _ _ _ + AT P.aeruginosa S S R S R _ _ _ _ S _
94 65 M R _ _ _ _ TT P.aeruginosa S S S R R _ _ _ _ S _
S
NO AGE SEX
EAR-
R/L/B
ASSOCIATED  FEATURES Type ofCSOM
Species
Identified ANTIBIOTIC SUSCEPTIBITITY TESTING
URTI ALLERGY TONSILLITIS DNS AK GM CIP PT CAZ COT CTX PEN ERY IMP CHLOR
RESIS
TANT
PATT
ERN
95 55 F R + _ _ + TT A.fumigatus
96 36 M R _ _ _ + TT S.aureus S _ S _ _ S _ S S _ S
97 45 F R + _ _ + TT P.aeruginosa S R R S R _ _ _ _ S _ ESBL
98 13 M L _ _ + + TT S.aureus S _ S _ _ S _ _ _ _ S
99 35 M R _ _ _ _ TT S.aureus S _ S _ _ S _ R S _ S
100 70 M R + _ _ + TT P.aeruginosa S S R S R _ _ _ _ S _ AmpC
AK AMIKACIN
GM GENTAMICIN
CIP CIPROFLOXACIN
PT PIPERACILLIN
TAZOBACTUM
CAZ CEFTAZIDIME
COT COTRIMOXAZOLE
CTX CEFOTAXIME
PEN PENICILLIN
ERY ERYTHROMYCIN
CX CEFOXITIN
IMP IMIPENEM
CHLOR CHLORAMPHENICOL
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